European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients

Haemophilia

Volumn 8, Issue SUPPL. 2, 2002, Pages 10-14

  Rothschild, C ^a   Scharrer, I ^b   Brackmann, H H ^c   Stieltjes, N ^d   Vicariot, M ^e   Torchet, M F ^a   Effenberger, W ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Hospital Cochin ^*  (France)

^e CHU MORVAN   (France)

Author keywords

Full length FVIII; Haemophilia A; Recombinant FVIII; Sucrose formulation

Indexed keywords

DETERGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; SOLVENT; SUCROSE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; DRUG PURIFICATION; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EUROPE; FRANCE; GERMANY; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; PRURITUS; RASH; SCHOOL CHILD; SKIN MANIFESTATION; VIRUS INACTIVATION;

ADOLESCENT; ADULT; BLOOD COMPONENT TRANSFUSION; CHILD; CONSUMER PRODUCT SAFETY; FACTOR VIII; HEMOPHILIA A; HUMANS; MIDDLE AGED; SUCROSE; TREATMENT OUTCOME;

EID: 0036257628     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-8216.2001.00131.x     Document Type: Article

References (11)

1. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A. conclusions of a 5-year study of home therapy
2. Transmission of hepatitis A to patients with haemophilia by FVIII concentrates treated with organic solvent and detergent to in-activate viruses
3. Hepatitis A virus infection among the haemophilia population at the Bonn Haemophilia Centre
4. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs
5. Hypoplastic anemia in a haemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus
6. Utilisation of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates
7. Note for guidance to assess efficacy and safety of human plasma derived factor VIII. C and factor IX. C products in clinical trials in hemophiliacs before and after authorisation
8. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardisation Committee of International Society for Thrombosis and Haemostasis
9. Experience with KOGENATE® Bayer in Surgical procedures
10. Discrepancy between one stage and chromogenic substrate assay results in the determination of FVIII recovery after infusion with rFVIII-FS
11. Sucrose formulated recombinant human antihaemophilic factor FVIII is safe and efficacious for treatment of haemophilia A in home therapy